A positive antiphospholipid antibody test means you have autoantibodies (eg, anticardiolipin, anti–β2‑glycoprotein I, or lupus anticoagulant) that can increase risk of blood clots and pregnancy loss. It does not by itself confirm antiphospholipid syndrome — diagnosis requires compatible clinical events plus persistent positivity on repeat testing after ≥12 weeks. Transient positivity can occur with infections or certain drugs; follow-up with your clinician is essential.

Antiphospholipid antibodies (aPL) are autoantibodies that target phospholipids or phospholipid‑binding proteins (notably cardiolipin, β2‑glycoprotein I) and include the lupus anticoagulant. They promote abnormal blood clotting by activating endothelial cells, platelets and complement, causing arterial/venous thromboses and pregnancy complications. Diagnosis requires detection of lupus anticoagulant, anticardiolipin or anti‑β2‑GPI antibodies on two occasions ≥12 weeks apart.

Antiphospholipid syndrome is associated with three main autoantibodies: lupus anticoagulant, anticardiolipin antibodies, and anti–beta‑2‑glycoprotein I antibodies. These antibodies raise the risk of blood clots and pregnancy complications. Diagnosis requires lab detection of one or more antibodies on two occasions at least 12 weeks apart, together with clinical features such as thrombosis or recurrent pregnancy loss.

Another name for antiphospholipid antibody is anticardiolipin antibody (aCL). These autoantibodies — which also include lupus anticoagulant and anti‑β2‑glycoprotein I — target phospholipid‑binding proteins and are associated with increased risk of thrombosis and pregnancy loss. Diagnostic testing commonly measures anticardiolipin, lupus anticoagulant, and anti‑β2‑glycoprotein I to identify antiphospholipid syndrome.

Antiphospholipid syndrome can be serious. It increases risk of dangerous blood clots (deep vein thrombosis, pulmonary embolism), stroke, and pregnancy complications including recurrent miscarriage and preeclampsia. Severity varies; some people need long-term anticoagulation and specialist monitoring to prevent organ damage. With timely diagnosis and treatment outcomes improve, but untreated APS can cause life‑threatening events.

If antiphospholipid antibodies are isolated and asymptomatic, manage cardiovascular risk and consider low‑dose aspirin only for high‑risk profiles. For thrombotic antiphospholipid syndrome, give long‑term anticoagulation (warfarin, INR usually 2–3; higher or specialist strategies for recurrent events). Direct oral anticoagulants are generally avoided in high‑risk APS. In pregnancy use low‑molecular‑weight heparin plus low‑dose aspirin; refer to specialists.